Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03025698 · ClinicalTrials.gov registry record · Phase 2
A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT03025698 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 51 participants.
The verdict
NCT03025698, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is a phase II, open label, multi-center, intra-patient dose escalation study to characterize the pharmacokinetics (PK) after oral administration of eltrombopag in combination with immunosuppressive therapy in pediatric patients with previously untreated or relapsed/refractory severe aplastic anemia or recurrent aplastic anemia.
Interventions
- DRUG Eltrombopag
- DRUG hATG
- DRUG CsA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-09-30 |
| Est. Completion | 2025-01-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03025698
The ClinicalTrials.gov registry entry for NCT03025698 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Eltrombopag is the first listed.
NCT03025698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03025698 about?
NCT03025698 is a clinical study titled "A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia". This is a phase II, open label, multi-center, intra-patient dose escalation study to characterize the pharmacokinetics (PK) after oral administration of eltrombopag in combination with immunosuppressive therapy in pediatric patients with previously untreated or relapsed/refractory severe aplastic an...
What is the current status of trial NCT03025698?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2017-09-30. Estimated completion is 2025-01-27.
What interventions are being tested in trial NCT03025698?
The interventions under investigation include: Eltrombopag (DRUG), hATG (DRUG), CsA (DRUG).
Who is sponsoring clinical trial NCT03025698?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.